ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2017
A 3D-Engineered Conformal Implant Releases DNA Nanocomplexs for Eradicating the Postsurgery Residual Glioblastoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- Advancing immunomodulation in organ transplantation: the therapeutic potential of self-assembled rapamycin nanoparticles in allograft rejection.Journal of nanobiotechnology · 2025Article
- Applications of hydrogels and nanoparticles in the treatment of traumatic brain injury.Frontiers in bioengineering and biotechnology · 2024Review
- Enrichment and sensing tumor cells by embedded immunomodulatory DNA hydrogel to inhibit postoperative tumor recurrence.Nature communications · 2023Article
- 3D printing of pharmaceuticals for disease treatment.Frontiers in medical technology · 2022Review
- Three-Dimensional Printing for Cancer Applications: Research Landscape and Technologies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Three-Dimensional Printing of Curcumin-Loaded Biodegradable and Flexible Scaffold for Intracranial Therapy of Glioblastoma Multiforme.Pharmaceutics · 2021Article
- Review
- Nanoparticle-hydrogel superstructures for biomedical applications.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Noninvasive in vivo 3D bioprinting.Science advances · 2020Article
- Digital Light Processing Based Three-dimensional Printing for Medical Applications.International journal of bioprinting · 2020Review
- Engineering approaches to studying cancer cell migration in three-dimensional environments.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Review
- 3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling.Advanced drug delivery reviews · 2018Review
- A 3D-Engineered Conformal Implant Releases DNA Nanocomplexs for Eradicating the Postsurgery Residual Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy has great promise for glioblastoma treatment; however, it remains a great challenge to efficiently deliver genes to the brain. The incomplete resection of glioblastoma always leads to poor prognosis. Here, a 3D-engineered conformal implant for eradicating the postsurgery residual glioblastoma is designed. This implant is constructed by 3D-printing technology to match the tumor cavity and release an oncolytic virus-inspired DNA nanocomplex to kill glioblastoma cells through apoptosis induction. Meanwhile, a 3D-engineered subcutaneous glioblastoma xenograft is built to mimic the resection tumor cavity in mice. Insertion of the implant into the glioblastoma resection cavity efficiently delays tumor recurrence and significantly prolongs overall survival. This study provides a proof-of-concept of glioblastoma therapy using a conformal implant that releases oncolytic DNA nanocomplexs. This strategy can lead to the development of future precision therapy for eradicating postsurgery residual tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.